An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
Phase of Trial: Phase III
Latest Information Update: 02 Jul 2014
At a glance
- Drugs Tapentadol (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors Grunenthal
- 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 28 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.